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ABSTRACT 
 
Upregulation of functional voltage-gated Na+ channels (VGSCs) occurs in metastatic 
human breast cancer (BCa) in vitro and in vivo. The present study aimed to ascertain 
the specific involvement of the ‘neonatal’ splice variant of Nav1.5 (nNav1.5), thought 
to be predominant, in the VGSC-dependent invasive behaviour of MDA-MB-231 
cells. Functional activity of nNav1.5 was suppressed by two different methods 
targeting nNav1.5: (i) small interfering RNA (siRNA), and (ii) a polyclonal antibody 
(NESO-pAb); effects upon migration and invasion were determined. nNav1.5 mRNA, 
protein and signalling were measured using real-time PCR, Western blotting, and 
patch clamp recording, respectively. Treatment with the siRNA rapidly reduced (by 
~90 %) the level of nNav1.5 (but not adult Nav1.5) mRNA, but the protein reduction 
was much smaller (~30 %), even after 13 days. Nevertheless, the siRNA reduced peak 
VGSC current density by 33 %, and significantly increased the cells’ sensitivity to 
nanomolar tetrodotoxin (TTX). Importantly, the siRNA suppressed in vitro migration 
by 43 %, and eliminated the normally inhibitory effect of TTX. Migrated MDA-MB-
231 cells expressed more nNav1.5 protein at the plasma membrane than non-migrated 
cells. Furthermore, NESO-pAb reduced migration by up to 42 %, in a dose-dependent 
manner. NESO-pAb also reduced Matrigel invasion without affecting proliferation. 
TTX had no effect on cells already treated with NESO-pAb. It was concluded that 
nNav1.5 is primarily responsible for the VGSC-dependent enhancement of invasive 
behaviour in MDA-MB-231 cells. Accordingly, targeting nNav1.5 expression/activity 
may be useful in clinical management of metastatic BCa. 
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INTRODUCTION 
 
Ion channels are major signalling complexes expressed in many tissues, where they 
have diverse involvement in cellular activity [1]. Consequently, an increasing body of 
evidence implicates ion channels in a wide variety of pathophysiological conditions 
[2, 3], including cancer [4]. In particular, voltage-gated ion channels (activated by a 
depolarizing shift in membrane potential), including those permeable to K+, Cl- and 
Na+, are widely expressed in a range of cancer cells [5]. Voltage-gated Na+ channels 
(VGSCs) have been detected in cell lines of human breast cancer (BCa) [6], prostate 
cancer (PCa) [7], lymphoma [8], small-cell lung cancer (SCLC) [9, 10], 
neuroblastoma [11] and melanoma [12]. Importantly, VGSC upregulation has also 
been found in human BCa, PCa and SCLC in vivo [6, 13-15].  
The highly specific VGSC blocker tetrodotoxin (TTX) has been shown to 
suppress a variety of in vitro cell behaviours associated with the metastatic cascade 
[16] in BCa, PCa and SCLC cells, including galvanotaxis, endocytic membrane 
activity, migration and invasion [7, 10, 17-22]. In PCa, TTX suppressed additional 
metastasis-associated cell behaviours including morphological development and 
process extension [23], vesicular patterning [24], lateral motility [25], adhesion [26] 
and gene expression [27]. Furthermore, putative VGSC blockers have been shown to 
inhibit proliferation of PCa cells [13, 28], and the VGSC-blocking anticonvulsants 
phenytoin and carbamazepine were found to directly inhibit secretion of prostate-
specific antigen (PSA) and interleukin-6 from LNCaP and PC-3 PCa cell lines, 
respectively [29].  
The VGSC proteins are comprised of a core α-subunit, which by itself can 
generate functional Na+ channels, together with one or more auxiliary, modulatory β-
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subunits [30]. In the metastatic MDA-MB-231 human BCa cell line, TTX-resistant 
(IC50 in µM range) functional VGSC activity was detected using the whole-cell patch 
clamp technique [6, 22]. In this cell line, the predominant isoform, TTX-resistant 
Nav1.5 alpha-subunit, was expressed ~1800-fold more at mRNA level, compared 
with the weakly metastatic cell line, MCF-7 [6]. In MDA-MB-231 cells, Nav1.5 
constituted over 80 % of the total VGSC α-subunit mRNA level, the remaining 20 % 
being mainly the TTX-sensitive Nav1.7 [6]. Interestingly, the Nav1.5 was expressed 
primarily in it’s ‘neonatal’ DI:S3 5’-splice form (nNav1.5), differing from the known 
DI:S3 3’-splice form at 31 out of 92 nucleotides, resulting in 7 amino acid differences 
[6]. In the nNav1.5 protein, as with developmentally regulated DI:S3 5’-splice 
variants of other VGSC subtypes [31], a highly conserved aspartate residue at the 
extracellular end of DI:S3 was replaced by a positively charged lysine [6, 32]. The 
DI:S3 5’-splice variant of Nav1.5 has also recently been described in a human 
neuroblastoma cell line [11].  
A novel polyclonal antibody (NESO-pAb) recognising an extracellular epitope 
(in DI:S3), specific to nNav1.5, but not ‘adult’ Nav1.5 was raised [32]. 
Immunohistochemistry with NESO-pAb confirmed that nNav1.5 was significantly 
more abundantly expressed in neonatal than adult heart and brain tissue samples [32]. 
Immunocytochemistry with NESO-pAb also revealed that nNav1.5 was indeed highly 
expressed in the plasma membrane of MDA-MB-231 but not MCF-7 cells [6]. 
Importantly, whole-cell patch clamp recording showed that direct application of 
NESO-pAb to modified human embryonic kidney (EBNA-293) cells expressing 
nNav1.5 reversibly blocked functional VGSC activity, whereas EBNA-293 cells 
expressing ‘adult’ Nav1.5 were ~400-fold less sensitive [32]. EBNA-293 cells are 
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frequently used for transfection studies, and two variants expressing ‘adult’ and 
‘neonatal’ forms of Nav1.5 were produced earlier [32]. 
Although we have previously shown that micromolar concentrations of TTX 
suppressed in vitro metastatic cell behaviours of BCa [6], the specific VGSC 
subtype(s) involved was not known. The aim of the present study was to ascertain the 
extent of involvement of nNav1.5 specifically in upregulating invasive activity in 
MDA-MB-231 cells. Two independent approaches targeting the functional 
expression/activity of this isoform were used: (i) RNA interference, and (ii) NESO-
pAb. Preliminary findings from this study have been published previously in abstract 
form [33]. 
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MATERIALS AND METHODS 
 
Cell culture 
MDA-MB-231 and PC-3M cells were cultured as described previously [6, 27]. Cells 
were seeded into Falcon tissue culture dishes (Becton-Dickinson, Oxford, UK) and 
incubated at 37 ˚C, 5 % CO2 and 100 % relative humidity. 
 
RNA interference 
Two different siRNAs targeting unique nucleotides within the 5’-DI:S3 alternatively 
spliced exon of nNav1.5 were designed using an online algorithm (Dharmacon, 
Lafayette, CO), as follows: 
 siNESO1 target sequence: 5’-UUUGUCGGCUCUUCGAACU-3’ 
 siNESO2 target sequence: 5’-GAGUCCUGAGAGCUCUAAA-3’ 
Their target specificity was ensured by nucleotide BLAST screening optimised for 
short sequences [34]. All siRNA duplexes were synthesised by Dharmacon and 
resuspended and stored according to the manufacturer’s instructions. Cells (70 % 
confluent in 6-well plates) were transfected for 4 h with siRNA (300 pmol/well) using 
Oligofectamine (Invitrogen, Paisley, UK), according to the manufacturer’s 
instructions. mRNA, protein level and functional activity were assayed 3-13 days 
post-transfection, and compared with mock or control siRNA-treated cells (siControl 
Non-Targeting siRNA 2). Transfection efficiency was assessed independently using a 
positive control siRNA (siControl Lamin A/C). 
 
Real-time PCR 
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Extraction of total RNA, synthesis of cDNA and real-time PCR were performed as 
described previously [15, 27], with NADH/cytochrome b5 reductase (Cytb5R) 
measured as a normalising gene. The following primer pairs and annealing 
temperatures were used:  
1. Cytb5R: 5’-TATACACCCATCTCCAGCGA-3’ and 5’-
CATCTCCTCATTCACGAAGC-3’; annealing temperature, 60 ˚C [35]. 
2. Adult Nav1.5: 5’-CATCCTCACCAACTGCGTGT-3’ and 5’-
ACATTGCCCAGGTCCACAAA-3’; annealing temperature, 60 ˚C. 
3. Neonatal Nav1.5: 5’-CATCCTCACCAACTGCGTGT-3’ and 5’-
CCTAGTTTTTCTGATACA-3’; annealing temperature, 58 ˚C. 
4. Nav1.7: 5’-TATGACCATGAATAACCCGC-3’ and 5’-
TCAGGTTTCCCATGAACAGC-3’; annealing temperature, 59 ˚C [35]. 
5. Lamin A/C: 5’-CTGCGGCGGGTGGATGCTGAGAAC-3’ and 5’-
CCACGGCTGCGCTGCGAGGTAGG-3’; annealing temperature, 67 ˚C. 
The threshold amplification cycles were determined using the Opticon Monitor 2 
software (MJ Research, Waltham, MA) and then analysed by the 2-∆∆Ct method [36].  
 
Western blotting 
Equivalent amounts of protein lysate (40 µg/well) were resolved by SDS 
polyacrylamide gel electrophoresis, as described previously [7, 32]. Three primary 
antibodies were used, at given dilutions, as follows: 
1. Pan-VGSC antibody (1 µg/ml; Upstate); 
2. NESO-pAb antibody (1 µl/ml) [32]; and 
3. Anti-actinin antibody (1 µl/ml; Sigma, Dorset, UK). 
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The secondary antibodies were peroxidase-conjugated swine anti-rabbit for 1 and 2, 
and goat anti-mouse for 3 (Dako, Glostrup, Denmark). Blots were developed with 
ECL (Amersham, Little Chalfont, Buckinghamshire, UK) and visualised by exposure 
to Super RX100NF film (Fujifilm, London, UK). Densitometric analysis was 
performed using the Image-Pro Plus software (Media Cybernetics). Signal intensity 
was normalised to anti-actinin antibody as a loading control/reference, for at least 
three separate treatments. For each antibody, linearity of signal intensity with respect 
to increasing protein loading in the range 20-80 µg was ensured using a standard 
dilution of MDA-MB-231 protein extract. 
 
Migration, proliferation and invasion assays 
Cells (2 x 105 /ml and 7.5 x 104 /ml, respectively) were plated onto 12 µm-pore 
Transwell migration filters in 12-well plates (Corning, NY), or Matrigel-coated 
invasion chambers in 24-well plates (Becton-Dickinson) according to the 
manufacturers’ instructions. Cells were incubated with or without TTX (10 µM), 
and/or NESO-pAb (0.01-20 µg/ml) in a 1-10 % FBS chemotactic gradient. The 
number of cells migrating over 7 h or invading over 24 h was determined using the 
thiazolyl blue tetrazolium bromide (MTT) assay [17]. Results were compiled as the 
mean of at least four repeats. A polyclonal rabbit anti-laminin antibody (10 µl/ml; 
Serotec, Oxford, UK) and a rabbit IgG fraction from healthy non-immunised rabbits 
(1 µg/ml; Dako) were used as controls for the NESO-pAb experiments. Proliferation 
was determined using the MTT assay [17], in at least five different experiments. 
 
Immunocytochemistry and confocal microscopy 
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Immunocytochemistry was performed as described previously [6, 32], with the 
following modifications: Cells were labelled with FITC-conjugated concanavalin A 
(Sigma) as a plasma membrane marker. The secondary antibody was Alexa567-
conjugated goat anti-rabbit IgG (Dako). 
Samples were viewed using a Leica DM IRBE microscope (with a X100 
objective) with a confocal laser scanner (Leica TCS-NT with Ar/Kr laser). FITC 
and/or Alexa567 were excited with the 488 nm and 568 nm laser lines, respectively. 
The images (512 x 512 pixels) were obtained simultaneously from two channels using 
a confocal pinhole of 226.98 µm (Airy 1).  
 
Digital image analysis 
Densitometric analysis was performed using the LCS Lite software (Leica), as 
follows: 
1. Cell surface VGSC expression was determined using the “freeform line 
profile” function drawn around the cell surface, determined by concanavalin A 
staining. Measurements were taken from 30 cells per condition, for three 
repeat treatments. 
2. Protein distribution was determined using the “straight line profile” function 
drawn across the cytoplasm avoiding the nucleus, as described previously [37-
39]. Signal intensity in plasma membrane region, set to cover 1.5 µm inward 
from the edge of concanavalin A staining, was compared with cytoplasmic 
signal intensity within the central 30 % of the line profile. Measurements were 
taken from ≥ 6 cells (randomly chosen) per condition, for three repeat 
treatments. 
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3. For analysing nNav1.5 staining in migrated vs. non-migrated cells, the 
“histogram profile” function was used to obtain measurements from the whole 
cell. Measurements were taken from ≥ 15 cells (chosen randomly) per 
condition, for three repeat treatments. 
 
Electrophysiology 
Whole-cell patch clamp recordings were performed 13 days after transfection, when 
patch pipettes could be successfully sealed upon cell membranes. The procedures 
used were mostly as described previously [40]. Voltage-activated membrane currents 
were recorded using an Axopatch 1D patch clamp amplifier (Axon Instruments, 
Wokingham, UK) compensating for series resistance by ~80 %. Currents were 
digitised using a Digidata 1200 interface (Axon Instruments), low-pass filtered at 5 
kHz, sampled at 50 kHz, and analysed using pClamp 6 software (Axon Instruments). 
Linear components of leak were subtracted using the leak subtraction facility on the 
amplifier and/or using the pClamp software.  
 Two voltage-clamp protocols were used (holding potential = -100 mV), as 
follows: 
1. Basic current-voltage (I-V) protocol: Cells were depolarised to test potentials 
within the range –70 to +70 mV in 5 mV steps. The test pulse duration was 60 
ms; the interpulse duration was 2 s. 
2. Steady-state inactivation protocol: Prepulses were in the range –130 to –10 
mV (10 mV steps) for durations of 1 s. A test pulse of –10 mV was 
immediately applied for 80 ms; the interpulse duration was 2 s. 
Recordings were obtained from a minimum of 20 cells per condition, from at least 
three repeat treatments. Data from individual dishes were combined to provide an 
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overall mean and standard error (SEM). Conductance-voltage relationships and curve 
fitting were performed as described previously [41]. TTX dose-repsonse data were 
fitted using Excel (Micosoft) and Origin (OriginLab, Northampton, MA) software to a 
double Langmuir adsoption isotherm: 
y = PTTXs [ 1 / ( 1 + [TTX] / IC50S )] + ( 1 – PTTXs ) [ 1 / ( 1 + [TTX] / IC50R )], 
where IC50S and IC50R are the concentrations of TTX for 50 % VGSC blockage, for 
the TTX-sensitive and TTX-resistant components, respectively; and PTTXs is the 
proportion of current that is TTX-sensitive [42]. 
 
Data analysis 
All quantitative data are presented as means ± standard errors, unless stated otherwise. 
Pairwise statistical significance was determined with Student's t test, or Mann-
Whitney rank sum test, as appropriate. Multiple comparisons were made using 
ANOVA followed by Newman-Keuls post-hoc analysis. Real-time PCR data were 
analysed using the 2-∆∆CT method [36]. Results were considered significant at P < 0.05 
(*). 
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RESULTS 
 
In the present study, the specific involvement of nNav1.5 in upregulating invasive 
behaviour in MDA-MB-231 cells was tested by two different approaches, aiming to 
suppress functional nNav1.5 activity with (i) RNA interference, and (ii) NESO-pAb. 
 
siRNA significantly reduced the nNav1.5 mRNA level 
MDA-MB-231 cells were transfected with a positive control siRNA targeting lamin 
A/C to confirm an efficient transfection protocol. After 3 days, the siRNA 
significantly reduced the lamin A/C mRNA level by 91 %, compared to mock-
transfected cells (P < 0.01; n = 3). Next, cells were transfected independently with one 
of two siRNAs (siNESO1 and 2) targeting nNav1.5. As both siRNAs produced very 
similar results, data hereon are presented from either. In siRNA-transfected cells, the 
nNav1.5 mRNA level was reduced by 82 % after 3 days (P < 0.05; n = 3), increasing 
to 91 % after 5 days (P < 0.001; n = 3), compared to mock-transfected cells (Figure 
1A). In contrast, after 5 days, the mRNA levels of adult Nav1.5 (aNav1.5) and Nav1.7 
were unaffected (P = 0.73; n = 3 for both; Figure 1B). After 9 days and 13 days, the 
reduction in nNav1.5 mRNA level was less marked but still significant, reaching 74 
% (P < 0.05; n = 3), and 65 % (P < 0.05; n = 3), respectively (Figure 1A), compared 
to cells transfected with non-targeting control siRNA (siControl).  
 
siRNA reduced the VGSC protein level 
Western blot with pan-VGSC and NESO-pAb antibodies revealed smaller reductions 
in the total VGSC α-subunit protein level of siRNA-transfected cells. After 3 days, 
protein was reduced by 24 % (P = 0.23; n = 6), and 23 % (P < 0.05; n = 3), for pan-
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VGSC and NESO-pAb, respectively, compared to mock-transfected cells (Figure 2A, 
B). Similarly, after 5 days, protein was reduced by 19 % (P = 0.06; n = 4), and 22 % 
(P = 0.17; n = 3), for pan-VGSC and NESO-pAb, respectively. The reduction in 
protein level persisted such that after 9 days, there was a reduction of 19 % (P < 0.05; 
n = 3), and 21 % (P = 0.19; n = 3), and after 13 days, protein was reduced by 26 % (P 
< 0.01; n = 3), and 25 % (P = 0.07; n = 3), for pan-VGSC and NESO-pAb, 
respectively, compared to cells transfected with siControl (Figure 2A, B).  
Consistent with the Western blot data, analysis of confocal images of cells 
labelled with NESO-pAb revealed that after 13 days, siRNA transfection had 
significantly reduced the level of nNav1.5 protein at the plasma membrane by 36 % 
(P < 0.001; n = 90; Figure 2C, D). However, the subcellular (plasma membrane vs. 
internal/cytoplasmic) distribution of nNav1.5 protein along cellular cross-sections was 
unchanged by the siRNA treatment. The level of nNav1.5 immunoreactivity in a 1.5 
µm section measured inward from the cell edge was assumed to represent the  
‘plasma membrane’ fraction; the middle 30 % of the cross-section was assumed to 
represent the ‘internal’ cytoplasmic fraction [39]. The relative levels of nNav1.5 
immunoreactivity for both fractions (expressed as a percentage of the total) were the 
same in control and siRNA-treated cells (P = 0.74 and P = 0.77, respectively; n = 20 
for each; Figure 2E).  
In conclusion, the reduction in the total VGSC protein by the siRNA treatment 
was much smaller and slower than the decrease in the nNav1.5 mRNA level. There 
was also a reduction in the level of VGSC at the plasma membrane. However, the 
balance of the subcellular distribution/(re)cycling of protein was not affected. 
 
siRNA reduced VGSC functional activity 
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The effect of siRNA on VGSC functional activity was assessed using whole-cell 
patch clamp electrophysiology, at the same stage, when recordings became possible. 
Thus, after 13 days, transfection with siRNA significantly reduced peak VGSC 
current density by 33 %, from 20.6 ± 2.5 pA/pF to 13.7 ± 1.6 pA/pF, compared to 
siControl (P < 0.05; n > 20 cells of each; Figure 3A-C; Table I). Treatment with 
siRNA had no effect on activation voltage, voltage for current peak, voltage 
dependence of activation or steady-state inactivation (Figure 4A; Table I). There was 
a slight enlargement of the window current in the siRNA-treated cells (Figure 4A 
inset). 
 The time to peak of VGSC current was significantly slower in the voltage 
range -20 to 15 mV in cells transfected with siRNA (Figure 4B). However, fast (τf) 
and slow (τs) time constants of inactivation at 0 mV, derived from fitting current 
inactivations to a double exponential function, were unaffected by the siRNA 
treatment (Table I). Thus, the siRNA treatment slowed the activation kinetics, 
consistent with a possible change in the functional VGSC isoform expression profile. 
The dose-dependent blockage of VGSC current in MDA-MB-231 cells by 
TTX was best fitted to a double Langmuir adsorption isotherm, with TTX-sensitive, 
and TTX-resistant components. The sensitivity of VGSC currents to low 
concentrations of TTX (< 2 µM) was increased in cells transfected with siRNA, 
compared to siControl-transfected cells (Figure 4C). The siRNA significantly 
increased sensitivity to 200 nM TTX, from 14.0 ± 3.9 % to 26.7 ± 4.1 % (P < 0.05; n 
= 6 cells of each; Table I). We concluded that by downregulating the level of TTX-
resistant nNav1.5 with siRNA, the relative proportion of the other TTX-sensitive 
VGSC isoform(s) was increased. The latter was likely to involve Nav1.7 [6] 
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Migrated cells expressed more VGSC protein than non-migrated cells 
Confocal immunocytochemistry with NESO-pAb was used to compare the nNav1.5 
protein expression in plasma membranes of cells that did/did not migrate through the 
Transwell filters (Figure 5A, B). Cells that migrated through the filter had 2.2-fold 
more plasma membrane nNav1.5 protein immunoreactivity compared with cells that 
did not migrate (P < 0.001; n > 45; Figure 5C). 
 
siRNA and NESO-pAb both suppressed VGSC-dependent migration and 
invasion 
These assays were performed also after 13 days, when the status of the VGSC 
signalling was known. Thus, transfection with siRNA significantly reduced the 
number of cells migrating through 12 µm-pore Transwell filters filter by 43 % 
compared to siControl-transfected cells (P < 0.05; n = 5; Figure 6A). When TTX was 
applied while the siControl-transfected cells were migrating, their migration was 
reduced by 53 % (P < 0.05; n = 4), as reported earlier (FRASER). Importantly, TTX 
applied to siRNA-transfected cells during the assay had no further effect on their 
migration (P = 0.78; n = 4). Thus, the VGSC-sensitive component of migration was 
completely suppressed by siRNA targeting nNav1.5. 
NESO-pAb, applied during Transwell assays, reduced migration in a dose-
dependent manner, reaching significance, 38 % reduction at 1 µg/ml (P < 0.001; n = 
7; Figure 6B). NESO-pAb (1 µg/ml) also reduced Matrigel invasion of MDA-MB-
231 cells by 49 % compared to control (P < 0.001; n = 7), but had no effect on human 
metastatic PCa PC-3M cells, in which functional Nav1.7 is dominant [35] (J. K. J. 
Diss, unpublished observation). IgG control and an unrelated anti-laminin antibody 
had no effect on invasiveness of MDA-MB-231 or PC-3M cells (Figure 6C). TTX (10 
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µM) reduced invasion of MDA-MB-231 cells by 50 % (P = 0.001; n = 7). 
Importantly, co-application of NESO-pAb (1 µg/ml) and TTX (10 µM) also reduced 
cell invasion by 47 % (P < 0.01; n = 7), but had no further effect compared to either 
NESO-pAb or TTX alone (P = 0.87 and 0.58, respectively; n = 7 for each; Figure 6C). 
None of the antibody treatments had any effect on proliferation of MDA-MB-231 or 
PC-3M cells (data not shown). 
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DISCUSSION 
 
The main findings of this study are as follows: (i) siRNA reduced nNav1.5 mRNA 
expression in MDA-MB-231 cells rapidly and almost completely. (ii) siRNA-induced 
protein-level reduction was slower and smaller, leading to decreased VGSC 
functional activity and increased sensitivity to low concentrations of TTX. (iii) 
Targeting nNav1.5 with siRNA eliminated the VGSC-dependent component of 
migration. (iv) Migrated cells expressed more plasma membrane nNav1.5 protein than 
non-migrated cells. (v) NESO-pAb also reduced migration and eliminated VGSC-
dependent invasion. The overall conclusion from this study is that it is indeed 
nNav1.5 that is primarily responsible for the VGSC-dependent potentiation of 
invasive behaviour in the MDA-MB-231 BCa cell line. These results agree with, and 
extend, our previous findings in vitro and in vivo [6]. 
 
Effects of RNAi on nNav1.5 mRNA and protein expression 
In this study, the unique DI:S3 5’-splice region at exon 6 of nNav1.5 was targeted 
with siRNA. Although RNAi has previously been used to target ion channels [43-45], 
including VGSC α-subunit [46, 47], this is the first report where siRNA has been 
used to specifically target one particular splice variant of a VGSC isoform. There are 
several potential technical problems associated with the RNAi technique, including 
off-target effects and poor mRNA/protein-level downregulation [48-50]. In this study, 
the effects of RNAi were monitored over a 13-day time-course at a hierarchy of 
levels: mRNA, protein (level and distribution) and functioning; basically the same 
effects were observed using the two different siRNAs. Although this duration would 
seem longer than most siRNA experiments, it was necessary (i) to perform the patch 
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clamp recordings to ascertain the level of VGSC signalling, and (ii) to enable 
correlation of the siRNA effects at the various levels in a systematic approach. The 
siRNA caused ~90 % reduction of nNav1.5 mRNA after 5 days, beyond which, the 
level started to partially recover, reaching ~70 % reduction by 13 days. A similar 
pattern of mRNA silencing has been reported previously [51]. Nevertheless, both 
adult Nav1.5, and Nav1.7 mRNA levels were not affected by this treatment, 
confirming the specificity of the siRNA for nNav1.5.  
The reduction of nNav1.5 protein level, detected by Western blot using 
NESO-pAb, was much smaller, becoming significant only after 13 days. A pan-
VGSC antibody gave similar results. Confocal immunocytochemistry with NESO-
pAb [32] showed that nNav1.5 was present at the cell surface, in agreement with 
previous observations [6], and that the siRNA reduced the level of nNav1.5 protein 
expressed at the plasma membrane, without changing the balance of its (re)cycling. At 
present, the dynamics of VGSC mRNA/protein expression in cancer cells are not 
known, and this could be compounded by activity-dependent (auto)regulation of 
VGSCs [39]. The apparent disparity between the time course and extent of target 
mRNA and protein-level reduction may, in part, be due to large stores of intracellular 
protein and/or slow turnover rates [52]. Such disparities have been seen before in 
siRNA experiments. For example, siRNA targeting vitamin K epoxide reductase gene 
reduced mRNA level after 3 days, but protein was not reduced until after 11 days 
[51]. Also, in human BCa cells, siRNA-induced protein downregulation persisted for 
at least 7 days [53]. Given that VGSC protein half-life is 18-26 h [54, 55] and that 
there was intense intracellular immunoreactivity with NESO-pAb, the slower and 
smaller reduction in nNav1.5 protein could be due to it being present in large quantity 
in internal stores and cycling to the plasma membrane persisting. 
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Involvement of nNav1.5 in the functional VGSC activity of MDA-MD-231 cells 
The siRNA treatment reduced the VGSC functional activity in MDA-MB-231 cells 
by 33 %, in agreement with the molecular data, suggesting a decrease in the 
availability of VGSC protein at the plasma membrane. Importantly, the siRNA was 
found also to increase the sensitivity of cells to TTX concentrations of < 2 µM. This 
implies that the proportion of TTX-sensitive functional VGSCs was increased after 
the siRNA treatment. This TTX-sensitive component is likely to be Nav1.7, which we 
have previously shown to constitute ~20 % of the VGSC α-subunit mRNA in MDA-
MB-231 cells [6]. This is consistent with the dose-response data (Figure 4C) showing 
an increase in the level of the TTX-sensitive component up to 20-25 % of total 
current. On the other hand, the slower time to peak recorded in siRNA-treated cells is 
unlikely to be due to an increased proportion of Nav1.7, because TTX-sensitive 
VGSCs tend to have faster kinetics than TTX-resistant VGSCs [56, 57]. This raises 
the possibility that downregulation of nNav1.5 may have induced secondary, knock-
on effects, e.g. alteration of the relative profile of β-subunits, which can have a 
marked influence on VGSC functional properties [58-60]. Further work is required to 
determine the functional consequences of the β-subunits and Nav1.7 expression in 
MDA-MB-231 cells. 
 
A role for nNav1.5 in potentiating metastatic activity 
MDA-MB-231 cells were shown to express significantly more nNav1.5 protein at the 
plasma membrane than weakly metastatic MCF-7 cells [6]. In addition, migrated 
MDA-MB-231 cells were found to express more plasma membrane nNav1.5 protein 
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than non-migrated cells. Together, these data suggest a correlation between surface 
expression of nNav1.5 and invasiveness in BCa, as in vivo [6]. 
In MDA-MB-231 cells, TTX (10 µM) treatment has been shown previously to 
suppress a variety of in vitro behaviours associated with the metastatic cascade, 
including galvanotaxis, endocytic membrane activity, migration and invasion, 
consistent with the involvement of TTX-resistant VGSC activity [6, 22]. The siRNA 
treatment reduced migration by 43 %, and this was not further suppressed by addition 
of TTX during the migration assay. Thus, the siRNA almost completely eliminated 
the VGSC-dependent component of the cells’ invasiveness. Furthermore, NESO-pAb, 
which can directly inhibit nNav1.5 functional activity [32], was found to reduce both 
the migration and invasion of MDA-MB-231 cells to a similar extent, without 
affecting their proliferation, when applied during the assays. Importantly, co-
application of TTX did not further reduce the cells’ invasiveness below that of NESO-
pAb alone. In addition, NESO-pAb had no effect on the invasion of PC-3M PCa cells, 
which, like the parent PC-3 cells (34), express primarily Nav1.7 [35] (J. K. J. Diss, 
unpublished observations), confirming further the specificity of NESO-pAb for 
nNav1.5. Furthermore, an anti-laminin antibody had no effect on the migration of 
MDA-MB-231 cells, consistent with the effect of NESO-pAb being specifically upon 
the nNav1.5 channel. Together, these data imply that nNav1.5 alone is primarily 
responsible for the VGSC-dependent potentiation of invasiveness in MDA-MB-231 
cells. In both approaches, one interesting characteristic was apparent: blocking VGSC 
activity by only ~30 % was sufficient to eliminate its potentiating effect upon 
migration or invasion. This would imply that the relationship between VGSC activity 
and migration/invasion enhancement is rather steep.  
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Clinical implications 
This work has important clinical implications, whereby reduction of nNav1.5 activity, 
e.g. generally with non-cytotoxic VGSC-blocking drugs [28], could result in 
suppression of metastatic BCa. More specifically, given that nNav1.5 expression is an 
oncofetal phenomenon [61] and is not present in normal Nav1.5-expressing adult 
tissues [6, 32], it appears to have the hallmarks of an ideal target for specific 
anticancer treatment utilising siRNA [62-64], and/or antibody [65]. 
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FIGURE LEGENDS 
 
Figure 1 
RNAi reduced nNav1.5, but not adult Nav1.5, or Nav1.7 mRNA level. (A) Time 
course of relative nNav1.5 mRNA level after transfection with siRNA targeting 
nNav1.5. Squares, data compared with mock-transfected control (no siRNA). Circles, 
data compared with siControl non-targeting siRNA. (B) Relative level of adult 
Nav1.5 and Nav1.7 mRNA 5 days after transfection with siControl, or siRNA 
targeting nNav1.5. VGSC mRNA levels were normalised relative to Cytb5R by the 2-
∆∆Ct method. Errors propagated through the 2-∆∆Ct analysis are shown. Significance: 
(*) P < 0.05, (**) P < 0.01, (***) P < 0.001. 
 
Figure 2 
RNAi reduced nNav1.5 protein level. (A) Western blot with 40 µg of total protein per 
lane from cells 13 days after treatment with (1) siControl or (2) siRNA targeting 
nNav1.5. Antibodies used: NESO-pAb, a pan-VGSC antibody, and an actinin 
antibody as a control for loading. The same membrane was stripped and re-blotted. 
(B) Time courses of nNav1.5 (light symbols) and total VGSC (dark symbols) protein 
levels (relative to actinin controls) after transfection with siRNA targeting nNav1.5. 
Squares, compared with mock-transfected control (no siRNA). Circles, compared 
with siControl non-targeting siRNA. (C) Typical confocal images of cells double-
immunolabelled with NESO-pAb (red) and concanavallin A plasma membrane 
marker (green) 13 days after transfection with siControl or siRNA targeting nNav1.5. 
(D) Relative peripheral nNav1.5 protein level in cells 13 days after transfection with 
siControl or siRNA targeting nNav1.5. (E) nNav1.5 protein distribution 
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(immunoreactivity) along subcellular cross-sections (% of total). Left-hand bars, 1.5 
µm sections measured inward from edge of concanavalin A staining; Right-hand bars, 
middle 30 % of cross-section. PM, plasma membrane; INT, internal. Data are 
presented as mean and SEM. Significance: (X) P > 0.05, (*) P < 0.05, (**) P < 0.01, 
(***) P < 0.001. 
 
Figure 3 
RNAi reduced peak VGSC current density after 13 days. (A) Typical whole-cell 
VGSC currents elicited by 60 ms depolarising voltage pulses between -70 mV and 
+70 mV applied from a holding potential of -100 mV: (i) a siControl-treated cell; (ii) 
a cell treated with siRNA targeting nNav1.5. (B) Quantitative comparison of peak 
current densities recorded in siControl-treated cells, and cells treated with siRNA 
targeting nNav1.5. (C) Mean current-voltage relationships for siControl-treated cells 
(dark circles), and cells treated with siRNA targeting nNav1.5 (light circles). Data are 
presented as mean ± SEM. Significance: (*) P < 0.05. 
 
Figure 4 
RNAi altered VGSC kinetics and TTX sensitivity after 13 days. (A) Mean 
availability-voltage (squares) and relative conductance (G/Gmax)-voltage relationships 
(circles) for siControl-treated cells (dark symbols) and cells treated with siRNA 
targeting nNav1.5 (light symbols). Control (solid lines) and siRNA data (dotted lines) 
are fitted with Boltzmann functions. The inset magnifies the voltage range (‘window’) 
in which current is activated and not fully inactivated. (B) Dependence of time to 
peak on membrane voltage for siControl-treated cells (dark squares), and cells treated 
with siRNA targeting nNav1.5 (light squares). Control (solid line) and siRNA data 
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(dashed line) are fitted with single exponential functions. (C) Reduction of VGSC 
current by TTX for control-treated cells (dark circles), and cells treated with siRNA 
targeting nNav1.5 (light circles). Control (solid line) and siRNA data (dashed line) are 
fitted to double Langmuir adsoption isotherms. Data are presented as mean ± SEM. 
Significance: (*) P < 0.05, (**) P< 0.01. 
 
Figure 5 
Migrated cells had more nNav1.5 protein at the plasma membrane than non-migrated 
cells after 16 h. (A and B) Typical confocal images of non-migrated and migrated 
cells in Transwell assays, respectively. Cells were non-permeabilized and double-
immunolabelled with NESO-pAb (red) and concanavalin A plasma membrane marker 
(green). (C) Relative nNav1.5 protein level in migrated cells, normalised with respect 
to the level in non-migrated cells. Significance: (***) P < 0.001. 
 
Figure 6 
siRNA and NESO-pAb reduced VGSC-dependent metastatic cell behaviour. (A) 
Relative number of cells migrating through a Transwell chamber over 7 h, 13 days 
after transfection with siControl, or siRNA targeting nNav1.5. Cells were treated with 
TTX (10 µM), or untreated during the migration assays. (B) Relative number of cells 
migrating through a Transwell chamber over 7 h, treated with 0.01-20 µg/ml NESO-
pAb during the assay. (C) Relative number of cells invading through Matrigel 
chamber over 24 h. MDA-MB-231 (white bars) and PC-3M (grey bars) cells were 
treated with IgG (1 µg/ml), anti-laminin (1:100), NESO-pAb (1 µg/ml) with/without 
TTX (10 µM) during the invasion assay. In both (B) and (C), data shown are with 
respect to corresponding control, untreated cells (treated as 100 %). Data are 
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presented as mean and SEM. Significance: (X) P > 0.05, (*) P < 0.05, (**) P < 0.01, 
(***) P < 0.001, relative to “control”, unless indicated. 
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Table I. Effect of siRNA on VGSC characteristics in MDA-MB-231 cells 
Parametera Control siRNA P 
Ip (pA/pF) 20.6 ± 2.5 13.7 ± 1.6 0.02* 
Va (mV) -52.0 ± 2.4 -49.6 ± 1.9 0.44 
Vp (mV) 1.3 ± 1.8 1.9 ± 3.0 0.86 
Activation V1/2 (mV) -17.2 ± 1.9 -16.0 ± 2.1 0.68 
Activation k (mV) 7.2 ± 0.5 7.9 ± 0.8 0.44 
Inactivation V1/2 (mV) -77.9 ± 1.7 -79.2 ± 2.2 0.70 
Inactivation k (mV) -5.3 ± 0.3 -6.1 ± 0.5 0.31 
Tp at 0 mV (ms) 1.7 ± 0.1 2.3 ± 0.2 0.02* 
τf at 0 mV (ms) 1.9 ± 0.3 1.9 ± 0.2 0.99 
τs at 0 mV (ms) 10.1 ± 0.8 11.4 ± 1.1 0.33 
Block by 200 nM TTX (%) 14.0 ± 3.9 26.7 ± 4.1 0.04* 
aAbbreviations: Ip, peak current density; Va, activation voltage; Vp, voltage at current peak; 
V1/2, half-(in)activation voltage; k, slope factor; Tp, time to peak; τf/s, fast/slow time 
constant of inactivation. Data expressed as mean ± SEM. 
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